Good data is essential for a successful study. Whilst analysis is important, standardisation in the clinic is imperative.

Posted:
30
August 2011

Good data is essential for a successful study. Whilst analysis is important, standardisation in the clinic is imperative.Although many may claim they are specialists in conducting TQT studies, few have the data to back this up. Our published data shows that over the past decade, Richmond Pharmacology�s studies have consistently produced less variability of QT measurements when compared directly with our competitors. This confirms that we are the leading research unit for cardiac safety studies - either as a one stop solution or in conjunction with our preferred partner core labs.At Richmond Pharmacology our mantra is good data in equals good data out.Our 10th Birthday PromiseWe are so confident and proud of our 100% success rate in TQT studies that should we fail to show assay sensitivity we will repeat the study at no cost to our sponsors.To take us up on our promise, contact our Business Development team today to discuss your TQT study needs

Latest news

Upcoming Event

The 41st Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

4 – 5 December 2020
The 41st Annual Scientific meeting focuses on international collaboration in the pursuit of drug discovery and drug development.
View event

Contributing to our community in 2020

December 17, 2020
Richmond Pharmacology has a long-standing tradition of supporting local, national, and international charities and 2020 is no exception.
Read more

Richmond Pharmacology supports Cardior Pharmaceuticals with the pioneering trial of an oligonucleotide-based drug in heart failure patients

December 14, 2020
Richmond Pharmacology is delighted to welcome the positive Phase Ib results of Cardior Pharmaceuticals lead compound CDR132L for heart failure.
Read more

Marking a milestone for gene editing

November 10, 2020
We are pleased to share that Richmond Pharmacology, in partnership with Intellia Therapeutics and the Royal Free Hospital, have treated the first patient in a landmark CRISPR/Cas9 clinical trial of NTLA-2001
Read more